If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 1 - 10 of 29

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion

Objective
A Phase 1/2 Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Protocol No
MIRATI-1719-001
Categories
Cancer, Other Skin, Thoracic Cancers, Gynecologic Cancers, Other Gastrointestinal, Early Phase/Multiple Disease Site Cancers, Lip, Oral Cavity and Pharynx, Melanoma, Skin, Esophagus, Bladder, Pancreas/Liver, Prostate, Skin Cancers, Kidney, Prostate and Urologic Cancers, Head and Neck Cancers, Colorectal, Gastrointestinal Cancers, Sarcoma, Breast Cancers

An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses

Objective
IIT-GEORGE-I-PREDICT
Protocol No
IIT-GEORGE-I-PREDICT
Categories
Cancer, Colorectal, Gynecologic Cancers, Esophagus, Other Urologic, Head and Neck Cancers, Early Phase/Multiple Disease Site Cancers, Esophagus, Skin Cancers, Stomach, Prostate and Urologic Cancers, Pancreas/Liver, Breast Cancers, Other Gastrointestinal, Sarcoma, Gastrointestinal Cancers, Lung, Thoracic Cancers

A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors

Objective
A First-in-Human, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors
Protocol No
XILIO-XTX301-01-02-001
Categories
Cancer, Gynecologic Cancers, Thoracic Cancers, Colorectal, Early Phase/Multiple Disease Site Cancers, Kidney, Other Skin, Pancreas/Liver, Other Urologic, Prostate and Urologic Cancers, Stomach, Skin Cancers, Head and Neck Cancers, Gastrointestinal Cancers, Sarcoma, Breast Cancers

Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab or REGN5678 (a PSMAxCD28 Bispecific Antibody) in Patients with Metastatic Castration-Resistant Prostate Cancer

Objective
To assess the safety, tolerability, and PK and to determine RP2DR of REGN4336
separately as monotherapy or in combination with cemiplimab.
Protocol No
REGENERON-R4336-ONC-20104
Categories
Cancer, Prostate and Urologic Cancers, Early Phase/Multiple Disease Site Cancers

An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations

Objective
An Open-label, Multicenter Study of LY4050784 in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations
Protocol No
LOXO-J5M-OX-JOXA
Categories
Cancer, Stomach, Prostate, Breast Cancers, Other Skin, Lip, Oral Cavity and Pharynx, Larynx, Ovary, Head and Neck Cancers, Thoracic Cancers, Sarcoma, Other Urologic, Pancreas/Liver, Cervix, Gynecologic Cancers, Esophagus, Melanoma, Skin, Bladder, Gastrointestinal Cancers, Prostate and Urologic Cancers, Early Phase/Multiple Disease Site Cancers, Skin Cancers

Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)

Objective
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Protocol No
SWOG-S2012
Categories
Cancer, Colorectal, Other Gastrointestinal, Prostate, Pancreas/Liver, Ovary, Early Phase/Multiple Disease Site Cancers, Bladder, Prostate and Urologic Cancers, Gynecologic Cancers, Gastrointestinal Cancers